1. EAU 2008 - Perioperative Use and Surgical Complications of Sunitinib in Metastatic Renal Cell Carcinoma
(Conference Coverage/EAU 2008 - Renal Cancer Highlights)

...ed their postoperative complication rate in patients having metastatic renal adenocarcinoma and treated with Sunitinib during the perioperative period. From October 2005 to June 2007, 52 patients ...

2. EAU 2008 - Perioperative Use and Surgical Complications of Sunitinib in Metastatic Renal Cell Carcinoma
(Browse Categories/Renal Cancer)

...ed their postoperative complication rate in patients having metastatic renal adenocarcinoma and treated with Sunitinib during the perioperative period. From October 2005 to June 2007, 52 patients ...

3. Beyond the Abstract - Pathological Evidence of Necrosis in Recurrent Renal Mass Following Treatment with Sunitinib
(Browse Categories/Beyond the Abstract - Renal Cancer)

BERKELEY, CA (UroToday.com) - Sunitinib is a highly potent, selective inhibitor of certain protein tyrosine kinases, including VEGF-R types 1 to 3, PDGF-R- , and PDGF-R-ß. Preclinical data suggest t

4. EAU 2008 - Safety and Efficacy of Sunitinib in an Expanded-Access Trial of Metastatic Renal Cell Carcinoma (mRCC): Updated Results and Subpopulation Analysis
(Browse Categories/Renal Cancer)

MILAN, ITALY (UroToday.com) - Sunitinib malate is an oral, multi-targeted tyrosine kinase inhibitor with direct anti-tumor and anti-angiogenic activities, internationally approved for the first-line t

5. EAU 2008 - Safety and Efficacy of Sunitinib in an Expanded-Access Trial of Metastatic Renal Cell Carcinoma (mRCC): Updated Results and Subpopulation Analysis
(Conference Coverage/EAU 2008 - Renal Cancer Highlights)

MILAN, ITALY (UroToday.com) - Sunitinib malate is an oral, multi-targeted tyrosine kinase inhibitor with direct anti-tumor and anti-angiogenic activities, internationally approved for the first-line t

6. Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors
(Browse Categories/Renal Cancer)

BERKELEY, CA (UroToday.com) - Sunitinib is an anti-angiogenic targeted therapy approved by the FDA this year for the treatment of both gastrointestinal stromal tumor (GIST) as well as metastatic renal

7. ASCO 2009 - Sunitinib in Patients with Unresectable Primary Renal Cell Carcinoma - Session Highlights
(Conference Coverage/ASCO 2009 - Renal Cancer Session HIghlights)

ORLANDO, FL, USA (UroToday.com) - In this study, the ability of sunitinib to shrink unresectable metastatic RCC was evaluated. Patients with histologically confirmed RCC, which was deeme

8. ASCO 2009 - Sunitinib in Patients with Unresectable Primary Renal Cell Carcinoma - Session Highlights
(Browse Categories/Renal Cancer)

ORLANDO, FL, USA (UroToday.com) - In this study, the ability of sunitinib to shrink unresectable metastatic RCC was evaluated. Patients with histologically confirmed RCC, which was deeme

9. Sunitinib Treatment for Patients with Clear-Cell Metastatic Renal Cell Carcinoma: Clinical Outcomes and Plasma Angiogenesis Markers - Abstract
(Browse Categories/Renal Cancer)

Sunitinib is a protein tyrosine kinase-inhibitor targeting VEGFR, c-kit and PDGFR. It has been approved for the treatment of metastatic renal-cell carcinoma and gastrointestinal stromal tumors. Althou

10. Sunitinib Malate Shows Anti-Tumour Activity In Metastatic Renal Cell Carcinoma
(Browse Categories/Renal Cancer)

...lar endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors and their pathways, sunitinib malate prolongs progression-free survival in patients with metastatic renal cell ...

11. CORRECTION: Sunitinib Malate Shows Anti-Tumour Activity In Metastatic Renal Cell Carcinoma
(Browse Categories/Renal Cancer)

...lar endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors and their pathways, sunitinib malate prolongs progression-free survival in patients with metastatic renal cell ...

12. EAU 2006 - ABST [1057] Sunitinib malate (SU11248) – efficacy in renal cell carcinoma (RCC)
(Conference Coverage/SELECTED ABSTRACTS)

EAU 2006 - ABST [1057] Sunitinib malate (SU11248) – efficacy in renal cell carcinoma (RCC) R. Motzer 1, B. Rini 2, D. Michaelson 3, B. Redman 4, G. Hudes 5, G. Wilding 6, R. Bukowski 7, D. Geo

13. ASCO 2009 - Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity - Session Highlights
(Conference Coverage/ASCO 2009 - Renal Cancer Session HIghlights)

...e object of this study was to identify genetic markers in the pharmacokinetic and pharmacodynamic pathway of sunitinib that predispose patients to the development of toxicities. This wa...

14. ASCO 2009 - Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity - Session Highlights
(Browse Categories/Renal Cancer)

...e object of this study was to identify genetic markers in the pharmacokinetic and pharmacodynamic pathway of sunitinib that predispose patients to the development of toxicities. This wa...

15. ASCO 2009 - A Phase II Study of Sunitinib on a Continuous Dosing Schedule in Patients with Relapsed or Refractory Urothelial Carcinoma - Session Highlights
(Conference Coverage/ASCO 2009 - Bladder Cancer Session Highlights)

ORLANDO, FL, USA (UroToday.com) - Sunitinib has demonstrated activity as a second-line agent for patients with advanced urothelial carcinoma (UC) when administered on a 4 week on, 2 week off schedule.